NPI Details
VITALITY DX LLC is a clinical medical laboratory in Lexington, KY. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. VITALITY DX LLC NPI is 1386246858. The provider is registered as an organization entity type.
The provider Is Doing Business As Sphere Dx.
The provider's business location address is:
2277 THUNDERSTICK DR STE 200
LEXINGTON, KY
ZIP 40505-882
Phone: (502) 830-9503
The provider's authorized official is Tamia Fisher .
The authorized official title is Credentialing and has the following contact phone number (812) 962-7894.
The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.
- Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
- Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
- Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
- Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
- Blood test, comprehensive group of blood chemicals (HCPCS:80053)
- Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
- Vitamin d-3 level (HCPCS:82306)
- Blood test, clotting time (HCPCS:85610)
- Prealbumin (protein) level (HCPCS:84134)
- Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)
- Coagulation assessment blood test, plasma or whole blood (HCPCS:85730)
- Glycated protein level (HCPCS:82985)
- Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
- Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
- Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
- Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
- Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets (HCPCS:87631)
- Hemoglobin a1c level (HCPCS:83036)
- Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
- Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
- Red blood cell sedimentation rate, to detect inflammation, automated (HCPCS:85652)
- Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
- Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
The enumeration date for this NPI number is 11/10/2020 and was last updated on 11/14/2022.
Taxonomy Codes
The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:
| No. |
Taxonomy Code |
Taxonomy Clasification |
Taxonomy Specialization |
License Number |
License State |
Primary |
| 1 | 291U00000X | Clinical Medical Laboratory | | | | Yes |
Other Identifiers
The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.
| No. |
Other Provider Identifier |
Other Provider Identifier Type |
Other Provider Identifier State |
Other Provider Identifier Issuer |
| 1 | 7100719120 | MEDICAID | KENTUCKY | |
| 2 | 18D2200531 | OTHER | KENTUCKY | CLIA |
